OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.
The combined firm will be based in Gaithersburg, Maryland and will focus on infectious disease diagnostics and antimicrobial resistance prediction services.
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
Of the 27 companies in the index, 14 firms' stocks were down, while 13 companies' share prices increased.
CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.
The proposed acquisitions follows two deals last month by PreCheck and is aimed at strengthening its point-of-care screening capabilities.
The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The merger is aimed at expanding Salveo’s diagnostics capabilities and improving communication with providers and patients.